These medications have shown promise in improving cognitive function and offering neuroprotective effects, especially in patients with metabolic disorders like type 2 diabetes
Plaintiffs contend that manufacturers knew or should have known about the association between GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy (NAION), yet omitted this critical information from drug labels and prescribing materials
Wegovy contains semaglutide and targets one hormone receptor
Further functional studies, such as gene knockout or silencing, are warranted to confirm their relevance
adults without diabetes used a GLP-1 [drug] in 2022," wrote the research team led by Michelle Dowsey, an epidemiologist with the University of Melbourne in Australia
Sometimes, the body works in unexpected ways